Health

The ongoing Ozempic and weight-loss drug obsession has investors and ETF issuers turning to new ways of gaining healthcare sector exposure.

Shares of major U.S. health insurers have taken a significant hit as the final 2025 Medicare Advantage plan payment rates fall short of industry expectations, raising concerns about margins.

Here's a look at some of the most interesting prospective ETFs awaiting regulatory review and approval as of March.

Health Care sector sees a modest 2023 finish after a decline in 2022, sparking renewed interest with substantial inflows this week.

Ozempic, Wegovy, and Mounjaro – here's how the latest weight-loss drugs could affect some pharmaceutical and food ETFs.

Dr. Sasha Goodman, Chief Investment Officer of VegTech Invest, joins Elysabeth Alfano, CEO of VegTech Invest to discuss what has happened to the Beyond Meat and Oatly stocks and, conversely, the large landscape of Plant-based Innovation companies in the public markets that are thriving.

Investors with a high tolerance for risk may seek to gain exposure to the growth potential of the biotech industry. We take a look at two ETFs that have rallied over the last month.